Tagged with Novartis,

Pharma Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia and industry in Switzerland, the effects of the foundation’s research, notably on Novartis, and future projects in the making. Could you begin by introducing both yourself and your institute to our…

Czech Republic There is frequent dialogue between the pharmaceutical industry, relevant regulatory authorities, and government stakeholders in the Czech Republic, but this dialogue is often strained. However, more frequent and constructive interaction between the myriad actors involved in Czech pharma and healthcare is helping push the industry to new heights.    Jan Žaloudík,…

Pharma The following chart shows the top pharma companies in Hungary ranked by sales value. Global giant Novartis leads the way with USD 240 million of sales, followed by domestic champion Egis with USD 150 million.  Click here to read more articles and interviews from Hungary

Pharma Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing Sandoz’s historic engagement with the Italian market? Sandoz began marketing in Italy back in 2000. My own background, meanwhile, was…

Pharma Novartis Italy’s Georg Schroeckenfuchs discusses the impact of the company’s global restructuring on the Italian affiliate, the significance of local manufacturing, new products, and how the Novartis has managed to become a market leader in Italy. A lot has been happening with Novartis globally lately: with big changes to the…

Pharma Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on their growth and business model and his commitment to driving change management to develop the affiliate’s future success. Grifols is…

France PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of access to innovation for patients in one of the world’s fastest-growing regions. You were appointed President of Novartis Latin America…

Novartis Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived in Turkey five months ago after working in China for two and a half years. Many executives in Turkey have…

Novartis The country president and general director of Novartis Morocco discusses the impact of the price cuts on the pharma market, the need to change the health culture in the country and the importance of Morocco as a hub.   As well as being the country president of Novartis Morocco, you…

Novartis Novartis strives for “creating solutions for patients that go beyond the pill”. The country head and next president of CANIFARMA discusses how the company is using new programs and technology to get innovation to patients, how the recent work of COFEPRIS is helping get drugs to patients faster and why…

innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients.   You have had…

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …